Lusutrombopag as pretreatment for liver biopsy following liver transplantation

Katano, Takumi; Sanada, Yukihiro; Okada, Noriki; Mizuta, Koichi

doi:10.1111/ped.13698

Cited by 1 publication

(1 citation statement)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Collectively, these results suggest that the standard regimen of lusutrombopag (3 mg/day for 7 days) is a safe and effective drug for thrombocytopenia in cirrhotic patients and can diminish the need for frequent platelet transfusions [45]. Along these lines, another case report indicated that lusutrombopag is effective pretreatment for liver biopsy following liver transplantation in a pediatric patient and suggested that additional studies are needed to expand its clinical indications [46].…”

Section: The New Approvalsmentioning

confidence: 99%

New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations

Bankston

Al‐Horani

2019

IJMS

View full text Add to dashboard Cite

This review provides details about three small molecules that were recently approved by the FDA for the treatment of thrombocytopenia. The new treatments include lusutrombopag, avatrombopag, and fostamatinib. The first two drugs are orally active thrombopoietin receptor (TPO-R) agonists which are FDA-approved for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Fostamatinib is orally active prodrug that, after activation, becomes spleen tyrosine kinase (SYK) inhibitor. Fostamatinib is currently used to treat chronic and refractory immune thrombocytopenia in patients who have had insufficient response to previous treatment. Chemical structures, available dosage forms, recommended dosing, pharmacokinetics, results of toxicity studies in animals, most frequent adverse effects, significant outcomes of the corresponding clinical trials, and their use in specific patient populations are thoroughly described. Described also is a comparative summary of the different aspects of five currently available therapies targeting TPO-R or SYK for the treatment of thrombocytopenia.

show abstract

Section: The New Approvalsmentioning

confidence: 99%